Biotech Stock Rises 70% on Painkiller Breakthrough

A biotech stock is skyrocketing 70% after a breakthrough in non-opioid pain treatment, while a vaccine giant is sliding as COVID-era sales continue to fade, and a soda giant is losing its fizz with declining profits. Read on to find out more!

Junior Mining Watch (Sponsored)

This $68M-Backed Gold Miner Is Nearing Production

A junior mining company in Canada’s Red Lake District just announced a significant breakthrough—bringing their fully permitted mine closer to production by 2025.

With 1.65 million ounces of high-grade gold, $68M in secured funding, and the backing of mining legend Frank Giustra, this company is rapidly advancing toward its first gold pour.

Infrastructure upgrades are already underway, and as gold prices are climbing, this could be a prime opportunity to get in before production starts.

Get the full details and the stock symbol here.

Futures 📈

What to Watch

Earnings:

• SolarBank Corp [SUUN]: Aftermarket

• Clipper Realty Inc. [CLPR]: Aftermarket

Economic Reports:

• Import price index [Jan]: 8:30 a.m.

• U.S. retail sales [Jan]: 8:30 a.m.

• Industrial production [Jan]: 9:15 a.m.

• Capacity utilization [Jan]: 9:15 a.m.

• Business inventories [Dec]: 10:00 a.m.

• Dallas Fed President Lorie Logan speaks: 3:00 p.m.

Beverages

Coca-Cola Europacific 2024 Profit Down, Expects Growth in 2025

Coca-Cola Europacific Partners plc [CCEP] reported a decline in profit for fiscal 2024, despite strong revenue growth.

The beverage giant posted €1.42 billion ($1.49B) in profit attributable to shareholders, down from €1.67 billion ($1.75B) the previous year.

Earnings per share dropped to €3.08 from €3.63.

Revenue, however, climbed 11.7% year-over-year, reaching €20.44 billion ($21.4B) compared to €18.3 billion ($19.17B) in 2023.

On an adjusted comparable and FX-neutral basis, revenue grew by 3.3%.

Looking ahead, the company expects further growth in 2025. It projects a 4% revenue increase on an adjusted comparable basis and a 7% rise in operating profit.

The outlook reflects steady demand and strategic pricing adjustments.

In addition to its financial results, Coca-Cola Europacific Partners unveiled a 12-month share buyback program worth up to €1 billion ($1.05B).

The program is subject to approval at the company’s 2025 Annual General Meeting.

As one of the largest independent Coca-Cola bottlers, CCEP will continue to focus on expanding its portfolio and improving operational efficiency, despite evolving consumer preferences and global market trends.

Pharmaceuticals

Moderna Shares Plunging as COVID Vaccine Sales Continue to Slide

Moderna [MRNA] posted a larger-than-anticipated quarterly loss as the company continues to scale back manufacturing due to falling demand for its COVID-19 vaccine.

The biotechnology firm reported a fourth-quarter loss of $2.91 per share, missing analysts’ expectations of a $2.68 loss.

This marks a stark contrast from the profit of $0.55 per share recorded in the same quarter last year.

The company attributes a part of the loss to a $238 million non-cash charge tied to terminating a contract manufacturing agreement.

Chief Financial Officer James Mock stated that the decision was made to reduce excess production capacity and avoid unnecessary expenses.

Moderna's total revenue is down 66% year-over-year to $966 million, although it slightly exceeded analysts’ projections of $942.84 million.

COVID-19 vaccine sales contributed $923 million, while its respiratory syncytial virus (RSV) shot generated $15 million.

The revenue decline was primarily due to an earlier U.S. launch of the updated COVID-19 vaccine, which shifted sales into the third quarter, along with weaker international demand.

Looking ahead, the company is continuing cost-cutting efforts, aiming to reduce cash expenses by $1 billion this year and an additional $500 million in 2026.

Moderna also reaffirmed its expectation for FDA approval of its RSV vaccine for high-risk adults aged 18 to 59 later in 2025.

Shares of the firm are down around 4.5% in premarket trading, extending a nearly 60% loss in 2024.

Aerospace Market (Sponsored)

This $3 Aviation Stock Is Gaining Altitude

Just like Tesla revolutionized the roads, one company is aiming to do the same for the skies.

With breakthrough electric aviation technology, strategic industry partnerships, and a rapidly growing market presence, this company is positioned to dominate an industry projected for massive growth.

This $3 stock is still under the radar, but as the demand for clean, electric air travel takes off, this company’s upside could be enormous.

Get the full report on this potential aviation disruptor.

Energy

Portland General Electric Reports Strong Revenue Growth in 2024

Portland General Electric Company [POR] reported a significant increase in annual profit, exceeding analyst expectations.

The company’s full-year earnings are $313 million, or $3.01 per share, up from $228 million, or $2.33 per share, in the previous year.

On an adjusted basis, excluding special items, earnings are at $327 million, or $3.14 per share, slightly surpassing Wall Street projections of $3.13 per share.

Revenue for the year is up 17.7% year-over-year, reaching $3.44 billion compared to $2.92 billion in 2023.

The strong financial results reflect the company’s continued efforts to enhance its operational efficiency and expand its customer base.

Portland General Electric’s earnings growth comes amid rising energy demand and ongoing investments in infrastructure and renewable energy projects.

The company has focused on modernizing its grid and increasing reliability, which has contributed to its positive financial performance.

Looking ahead, the company remains optimistic about sustaining growth, with continued investments in sustainable energy initiatives and improvements in service delivery.

Virpax Pharmaceuticals, Inc. [VRPX] - Last Close: $0.29

Virpax Pharmaceuticals is a biopharmaceutical company focused on developing non-addictive pain management solutions and treatments for CNS disorders and antiviral barriers.

Its shares are skyrocketing 70%+ during premarket after announcing positive study results for Probudur™, a long-acting local anesthetic being developed in collaboration with the U.S. Army Institute of Surgical Research (USAISR).

Nu Skin Enterprises, Inc. [NUS] - Last Close: $6.42

Nu Skin Enterprises is a global personal care and wellness company specializing in direct sales of skincare and nutritional products.

Its shares are jumping 24% in early trade after it gave a better-than-expected Q4 earnings report, with EPS of $0.38, beating analysts' expectations of $0.22.

Roku, Inc. [ROKU] - Last Close: $86.80

Roku is a leading streaming platform. Its shares are surging in premarket after beating Q4 revenue estimates and issuing a strong 2025 revenue forecast.

Q4 revenue hit $1.20 billion, surpassing estimates of $1.15 billion. This was driven by a 25% growth in its ad-supported platform segment, which brought in $1.04 billion.

Gold (Sponsored)

This Gold Miner Could Be on the Verge of a Breakout

A high-grade gold project in Canada’s Red Lake District is making major strides toward restarting production. With 1.65 million ounces of gold, $68M in secured funding, and a fully permitted mine, this company is well-positioned for a breakout year.

Backed by mining titan Frank Giustra, this junior miner is accelerating toward a 2025 production target, and a recent update has strengthened its outlook.

With gold prices near all-time highs and institutional interest growing, this could be one of the biggest gold mining stories of the year.

Find out more about this stock before the market catches on.

Everything Else

• Sensient Technologies rebounds with higher sales and improved profitability.

• India and the U.S. strengthen ties with defense deals and AI collaboration.

• Hermes defies a luxury slowdown with strong fourth-quarter sales growth.

• Applied Materials forecasts weaker revenue as China sales face new hurdles.

• Palo Alto Networks’ revenue rises, but weaker guidance pressures shares.

• Airbnb plans new travel ventures after reporting impressive quarterly growth.

• Motorola Solutions expands its security offerings and forecasts steady revenue growth.

• Republic Services forecasts steady growth in 2025 after beating Q4 estimates.

• China struggles to retain foreign investment as billions flow out of the country.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.